Blocking this pathway is very important because otherwise cancer cells can easily slip through without being identified by the immune system. With Opdivo’s proven efficacy, for the first time a PD-1 inhibitor has shown significant survival for lung cancer patients. The company will reap in substantial benefits from its first-move advantage in the long run.